PFCS
FULC icon

Pale Fire Capital SE’s Fulcrum Therapeutics FULC Stock Holding History

Pale Fire Capital SE’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,100
Closed -$200K – 76
2026
Q1 		$200K Buy
+26,100
New +$242K 0.02% 55

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pale Fire Capital SE's FULC Position: Q2 2026 in Review

Pale Fire Capital SE sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 26,100 shares — an estimated $200K sold.

Pale Fire Capital SE first reported a position in FULC in Q1 2026 and held it in 1 quarter. The position peaked at $200K in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Pale Fire Capital SE reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Pale Fire Capital SE sold 26,100 Fulcrum Therapeutics shares in Q2 2026, an estimated $200K.
  • Pale Fire Capital SE first reported a position in Fulcrum Therapeutics in Q1 2026 and held it in 1 quarter.
  • Pale Fire Capital SE's Fulcrum Therapeutics position peaked at $200K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.